SPECTRUM PHARMACEUTICALS INC

2021 Q1 Form 10-Q Financial Statement

#000083154721000039 Filed on May 13, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $162.9M $177.8M
YoY Change -8.38% -41.88%
Cash & Equivalents $69.52M $70.35M
Short-Term Investments $93.30M $107.4M
Other Short-Term Assets $3.500M $10.30M
YoY Change -66.02% -14.17%
Inventory
Prepaid Expenses
Receivables $64.00K $435.0K
Other Receivables $2.800M $8.800M
Total Short-Term Assets $169.2M $197.3M
YoY Change -14.23% -42.02%
LONG-TERM ASSETS
Property, Plant & Equipment $3.613M $12.06M
YoY Change -70.04% 2487.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.363M $3.187M
YoY Change 36.9% -61.04%
Total Long-Term Assets $9.800M $18.71M
YoY Change -47.63% 50.66%
TOTAL ASSETS
Total Short-Term Assets $169.2M $197.3M
Total Long-Term Assets $9.800M $18.71M
Total Assets $179.0M $216.0M
YoY Change -17.12% -38.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $33.60M $26.90M
YoY Change 24.91% -35.65%
Accrued Expenses $13.80M $10.30M
YoY Change 33.98% -40.12%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $47.38M $53.70M
YoY Change -11.77% -23.64%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $9.189M $8.526M
YoY Change 7.78% -12.9%
Total Long-Term Liabilities $9.189M $8.526M
YoY Change 7.78% -12.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $47.38M $53.70M
Total Long-Term Liabilities $9.189M $8.526M
Total Liabilities $56.57M $62.22M
YoY Change -9.09% -22.33%
SHAREHOLDERS EQUITY
Retained Earnings -$921.0M -$765.0M
YoY Change 20.39% 23.58%
Common Stock $154.0K $114.0K
YoY Change 35.09% 2.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $122.4M $153.8M
YoY Change
Total Liabilities & Shareholders Equity $179.0M $216.0M
YoY Change -17.12% -38.75%

Cashflow Statement

Concept 2021 Q1 2020 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000831547
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 us-gaap Depreciation
Depreciation
0 USD
CY2020Q1 us-gaap Depreciation
Depreciation
0 USD
CY2021Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
CY2020Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
CY2021Q1 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-35006
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
SPECTRUM PHARMACEUTICALS INC
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
93-0979187
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
11500 South Eastern Avenue
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 240
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Henderson
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89052
CY2021Q1 dei City Area Code
CityAreaCode
702
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
835-6300
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2021Q1 dei Trading Symbol
TradingSymbol
SPPI
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
161520572 shares
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
69521000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46009000 USD
CY2021Q1 us-gaap Short Term Investments
ShortTermInvestments
93336000 USD
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
134016000 USD
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
64000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
67000 USD
CY2021Q1 us-gaap Nontrade Receivables
NontradeReceivables
2795000 USD
CY2020Q4 us-gaap Nontrade Receivables
NontradeReceivables
2394000 USD
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3491000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4161000 USD
CY2021Q1 us-gaap Assets Current
AssetsCurrent
169207000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
186647000 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3613000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3577000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1824000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2247000 USD
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4363000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4327000 USD
CY2021Q1 us-gaap Assets
Assets
179007000 USD
CY2020Q4 us-gaap Assets
Assets
196798000 USD
CY2021Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
42412000 USD
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
43771000 USD
CY2021Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
4967000 USD
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
9375000 USD
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
47379000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
53146000 USD
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9189000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9409000 USD
CY2021Q1 us-gaap Liabilities
Liabilities
56568000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
62555000 USD
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
153728336 shares
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
153728336 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
146083110 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
146083110 shares
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
154000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
146000 USD
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1046784000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1021221000 USD
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3507000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1829000 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-920992000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-885295000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
122439000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
134243000 USD
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
179007000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
196798000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14315000 USD
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14794000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19371000 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15993000 USD
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
33686000 USD
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
30787000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-33686000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-30787000 USD
CY2021Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
84000 USD
CY2020Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
704000 USD
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2081000 USD
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10534000 USD
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1997000 USD
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9830000 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35683000 USD
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40617000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7000 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-35676000 USD
CY2020Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-40617000 USD
CY2021Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-21000 USD
CY2020Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
45000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-35697000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-40572000 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.25
CY2020Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.36
CY2021Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare
-0.00
CY2020Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare
0.00
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
145371657 shares
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
111780571 shares
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-35697000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-40572000 USD
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1118000 USD
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-914000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-560000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-415000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1678000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1329000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37375000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41901000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
134243000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-35697000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1678000 USD
CY2020Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-40617000 USD
CY2021Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-21000 USD
CY2020Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
45000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4212000 USD
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
21357000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
122439000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
190393000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-40572000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1329000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5010000 USD
CY2020Q1 sppi Adjustments To Additional Paid In Capital Share Based Compensation Employee Benefit Plan
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeBenefitPlan
265000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
153768000 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-35676000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-35697000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-40572000 USD
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
65000 USD
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
140000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4212000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5275000 USD
CY2021Q1 sppi Operating Lease Noncash Lease Expense
OperatingLeaseNoncashLeaseExpense
401000 USD
CY2020Q1 sppi Operating Lease Noncash Lease Expense
OperatingLeaseNoncashLeaseExpense
381000 USD
CY2021Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-68000 USD
CY2020Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
51000 USD
CY2021Q1 us-gaap Equity Securities Fv Ni Realized Gain
EquitySecuritiesFvNiRealizedGain
2856000 USD
CY2020Q1 us-gaap Equity Securities Fv Ni Realized Gain
EquitySecuritiesFvNiRealizedGain
189000 USD
CY2021Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-4999000 USD
CY2020Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-10238000 USD
CY2021Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
324000 USD
CY2020Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-762000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-670000 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
960000 USD
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
36000 USD
CY2020Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-823000 USD
CY2021Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1681000 USD
CY2020Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-3919000 USD
CY2021Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-4408000 USD
CY2020Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-3118000 USD
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
96000 USD
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2153000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34491000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33343000 USD
CY2021Q1 us-gaap Proceeds From Maturities Repayments And Calls Of Trading Securities Heldforinvestment
ProceedsFromMaturitiesRepaymentsAndCallsOfTradingSecuritiesHeldforinvestment
49823000 USD
CY2020Q1 us-gaap Proceeds From Maturities Repayments And Calls Of Trading Securities Heldforinvestment
ProceedsFromMaturitiesRepaymentsAndCallsOfTradingSecuritiesHeldforinvestment
50966000 USD
CY2021Q1 us-gaap Proceeds From Sale Of Trading Securities Heldforinvestment
ProceedsFromSaleOfTradingSecuritiesHeldforinvestment
2858000 USD
CY2020Q1 us-gaap Proceeds From Sale Of Trading Securities Heldforinvestment
ProceedsFromSaleOfTradingSecuritiesHeldforinvestment
0 USD
CY2021Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
15964000 USD
CY2020Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
10208000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
73000 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1395000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
36644000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
39363000 USD
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
21357000 USD
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21357000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2000 USD
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-86000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
23512000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5934000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46009000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64418000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69521000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70352000 USD
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
620000 USD
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
593000 USD
CY2021Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4000 USD
CY2020Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
27000 USD
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2772000 USD
CY2021Q1 sppi Number Of Late Stage Development Products
NumberOfLateStageDevelopmentProducts
3 product
CY2021Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2021Q1 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
18136000 USD
CY2021Q1 sppi Deferred Compensation Investments Fair Value Disclosure
DeferredCompensationInvestmentsFairValueDisclosure
4039000 USD
CY2021Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
157600000 USD
CY2021Q1 us-gaap Deferred Compensation Liability Current And Noncurrent
DeferredCompensationLiabilityCurrentAndNoncurrent
9709000 USD
CY2021Q1 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
9709000 USD
CY2020Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
24946000 USD
CY2020Q4 sppi Deferred Compensation Investments Fair Value Disclosure
DeferredCompensationInvestmentsFairValueDisclosure
3963000 USD
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
178548000 USD
CY2020Q4 us-gaap Deferred Compensation Liability Current And Noncurrent
DeferredCompensationLiabilityCurrentAndNoncurrent
9783000 USD
CY2020Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
9783000 USD
CY2020Q4 us-gaap Deferred Compensation Liability Current And Noncurrent
DeferredCompensationLiabilityCurrentAndNoncurrent
9800000 USD
CY2021Q1 us-gaap Equity Securities Fv Ni Cost
EquitySecuritiesFvNiCost
3537000 USD
CY2021Q1 sppi Equity Securities Fvni Accumulated Foreign Currency Translation Gain Loss
EquitySecuritiesFVNIAccumulatedForeignCurrencyTranslationGainLoss
-2097000 USD
CY2021Q1 sppi Equity Securities Fvni Accumulated Unrealized Gain
EquitySecuritiesFVNIAccumulatedUnrealizedGain
16696000 USD
CY2021Q1 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
18136000 USD
CY2021Q1 sppi Cash Cash Equivalents And Shortterm Investments Amortized Cost
CashCashEquivalentsAndShorttermInvestmentsAmortizedCost
147211000 USD
CY2021Q1 sppi Equity Securities Fvni Accumulated Foreign Currency Translation Gain Loss
EquitySecuritiesFVNIAccumulatedForeignCurrencyTranslationGainLoss
-2097000 USD
CY2021Q1 sppi Cash Cash Equivalents And Shortterm Investments Accumulated Unrealized Gain
CashCashEquivalentsAndShorttermInvestmentsAccumulatedUnrealizedGain
17743000 USD
CY2021Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
162857000 USD
CY2020Q4 us-gaap Equity Securities Fv Ni Cost
EquitySecuritiesFvNiCost
3764000 USD
CY2020Q4 sppi Equity Securities Fvni Accumulated Foreign Currency Translation Gain Loss
EquitySecuritiesFVNIAccumulatedForeignCurrencyTranslationGainLoss
-1546000 USD
CY2020Q4 sppi Equity Securities Fvni Accumulated Unrealized Gain
EquitySecuritiesFVNIAccumulatedUnrealizedGain
22728000 USD
CY2020Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
24946000 USD
CY2020Q4 sppi Cash Cash Equivalents And Shortterm Investments Amortized Cost
CashCashEquivalentsAndShorttermInvestmentsAmortizedCost
157712000 USD
CY2020Q4 sppi Equity Securities Fvni Accumulated Foreign Currency Translation Gain Loss
EquitySecuritiesFVNIAccumulatedForeignCurrencyTranslationGainLoss
-1546000 USD
CY2020Q4 sppi Cash Cash Equivalents And Shortterm Investments Accumulated Unrealized Gain
CashCashEquivalentsAndShorttermInvestmentsAccumulatedUnrealizedGain
23859000 USD
CY2020Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
180025000 USD
CY2021Q1 sppi Other Receivables Miscellaneous
OtherReceivablesMiscellaneous
1239000 USD
CY2020Q4 sppi Other Receivables Miscellaneous
OtherReceivablesMiscellaneous
901000 USD
CY2021Q1 us-gaap Income Tax Receivable
IncomeTaxReceivable
1297000 USD
CY2020Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
1297000 USD
CY2021Q1 us-gaap Interest Receivable
InterestReceivable
259000 USD
CY2020Q4 us-gaap Interest Receivable
InterestReceivable
196000 USD
CY2021Q1 us-gaap Nontrade Receivables
NontradeReceivables
2795000 USD
CY2020Q4 us-gaap Nontrade Receivables
NontradeReceivables
2394000 USD
CY2021Q1 us-gaap Deposit Assets
DepositAssets
2022000 USD
CY2020Q4 us-gaap Deposit Assets
DepositAssets
1996000 USD
CY2021Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1469000 USD
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2165000 USD
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3491000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4161000 USD
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6544000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6445000 USD
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2931000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2868000 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3613000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3577000 USD
CY2020 us-gaap Asset Impairment Charges
AssetImpairmentCharges
19700000 USD
CY2021Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
33578000 USD
CY2020Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
34385000 USD
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1415000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1544000 USD
CY2021Q1 sppi Accrued Commercial Product
AccruedCommercialProduct
7419000 USD
CY2020Q4 sppi Accrued Commercial Product
AccruedCommercialProduct
7842000 USD
CY2021Q1 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
42412000 USD
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
43771000 USD
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
20523000 USD
CY2020 sppi Allowance For Credit Losses
AllowanceForCreditLosses
12681000 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
7842000 USD
CY2021Q1 sppi Allowance For Credit Losses
AllowanceForCreditLosses
423000 USD
CY2021Q1 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
7419000 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4212000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5275000 USD
CY2020Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5300000 USD
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
5300000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1824000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2247000 USD
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1415000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1544000 USD
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
567000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
883000 USD
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1982000 USD
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2427000 USD
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
466000 USD
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
466000 USD
CY2021Q1 us-gaap Variable Lease Cost
VariableLeaseCost
125000 USD
CY2020Q1 us-gaap Variable Lease Cost
VariableLeaseCost
114000 USD
CY2021Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
17000 USD
CY2020Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
15000 USD
CY2021Q1 us-gaap Lease Cost
LeaseCost
608000 USD
CY2020Q1 us-gaap Lease Cost
LeaseCost
595000 USD
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y4M24D
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.078
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y7M6D
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.078
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1182000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
828000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
87000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2097000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
115000 USD
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1982000 USD
CY2019Q2 sppi Licensors Annual License Maintenance
LicensorsAnnualLicenseMaintenance
2 product
CY2021Q1 us-gaap Deferred Compensation Liability Current And Noncurrent
DeferredCompensationLiabilityCurrentAndNoncurrent
9700000 USD
CY2019Q2 sppi Sale Of Common Stock Maximum Proceeds From Agreement
SaleOfCommonStockMaximumProceedsFromAgreement
150000000 USD
CY2020Q2 sppi Sale Of Common Stock Maximum Proceeds From Agreement
SaleOfCommonStockMaximumProceedsFromAgreement
75000000 USD
CY2020Q4 sppi Sale Of Common Stock Maximum Proceeds From Agreement
SaleOfCommonStockMaximumProceedsFromAgreement
60000000 USD
CY2019 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
221529 shares
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1814000 USD
CY2020 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3950398 shares
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14902000 USD
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5678893 shares
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
21357000 USD

Files In Submission

Name View Source Status
0000831547-21-000039-index-headers.html Edgar Link pending
0000831547-21-000039-index.html Edgar Link pending
0000831547-21-000039.txt Edgar Link pending
0000831547-21-000039-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sppi-20210331.htm Edgar Link pending
sppi-20210331.xsd Edgar Link pending
sppi-20210331_cal.xml Edgar Link unprocessable
sppi-20210331_def.xml Edgar Link unprocessable
sppi-20210331_g1.jpg Edgar Link pending
sppi-20210331_htm.xml Edgar Link completed
sppi-20210331_lab.xml Edgar Link unprocessable
sppi-20210331_pre.xml Edgar Link unprocessable
sppi20210331ex311.htm Edgar Link pending
sppi20210331ex312.htm Edgar Link pending
sppi20210331ex321.htm Edgar Link pending
sppi20210331ex322.htm Edgar Link pending